Actively Recruiting
Multicenter Prospective Cohort Study of Tumors With POLE and POLD1 Mutations
Led by Federation Francophone de Cancerologie Digestive · Updated on 2024-07-08
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying tumors that have specific mutations in the POLE or POLD1 genes across all stages and primary sites. The main goal is to identify and describe the clinical, biological, and molecular features of these tumors. This observational study gathers important information to better understand how these mutations affect cancer characteristics and patient outcomes. Patients are identified through tumor genotyping platforms, which detect these POLE or POLD1 mutations. These platforms notify the project coordination team and the lead investigator about new cases. The study collects diagnostic and follow-up data prospectively from patients with these mutations, regardless of tumor stage or site. Participants will have their tumor data entered and monitored over time, including molecular characteristics, overall survival, and response to treatments. The research team will maintain a database and tissue block library for ongoing analysis. The study is expected to continue through October 2027, with data collection and follow-up occurring during this period.
CONDITIONS
Brief Title
Cohort of Tumors With POLE/D1 Mutation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Tumor with a pathogenic variant in the exonuclease domain of POLE (exons 9 to 14) or POLD1 (exons 8 to 12) as classified by the project group
- Tumor diagnosis made at cohort launch date or within the previous year
- Participant is 18 years of age or older
You will not qualify if you...
- Tumor without POLE or POLD1 mutation
- Tumor with POLE mutation identified only in retrospective research studies
- Patient does not consent to data registration in the cohort
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed. Diagnostic and follow-up data are collected prospectively to characterize tumors with POLE/POLD1 mutations and track overall survival and treatment response.
Periodic visits as part of routine care
Trial Site Locations
Total: 1 location
1
CHU -hopital Rangeuil
Toulouse, France, 31059
Actively Recruiting
Research Team
R
ROSINE GUIMBAUD, PhD.MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here